Seven US Democratic Senators are reportedly calling or regulators to review the proposed acquisition of Allergan, which makes Botox, by Canada’s Valeant Pharmaceuticals.
According to reports, lawmakers want the $54 billion hostile takeover offer reviewed, citing former Valeant buyouts that lead to job cuts.
The company reportedly cut hundreds of jobs in New York after buying Bausch + Lomb.
Allergan twice has rejected Valeant’s buyout offers, claiming they severely undervalue the US pharmaceutical company. Valeant then joined Allergan shareholder Pershing Square Capital Management for the latest bid in efforts to oust the board of directors to secure the acquisition deal.
Full content: Democrat and Chronicle
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI